{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:02:24Z","timestamp":1793163744112,"version":"4.5.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009002","name":"Ministry of Education and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In response to the growing global threat of fungal infections, in 2020 the World Health Organisation (WHO) established an Expert Group to identify priority fungi and develop the first WHO fungal priority pathogen list (FPPL). The aim of this systematic review was to evaluate the features and global impact of invasive infections caused by Pichia kudriavzevii (formerly known as Candida krusei). PubMed and Web of Science were used to identify studies published between 1 January 2011 and 18 February 2021 reporting on the criteria of mortality, morbidity (defined as hospitalisation and length of stay), drug resistance, preventability, yearly incidence, and distribution\/emergence. Overall, 33 studies were evaluated. Mortality rates of up to 67% in adults were reported. Despite the intrinsic resistance of P. kudriavzevii to fluconazole with decreased susceptibility to amphotericin B, resistance (or non-wild-type rate) to other azoles and echinocandins was low, ranging between 0 and 5%. Risk factors for developing P. kudriavzevii infections included low birth weight, prior use of antibiotics\/antifungals, and an underlying diagnosis of gastrointestinal disease or cancer. The incidence of infections caused by P. kudriavzevii is generally low (\u223c5% of all Candida-like blood isolates) and stable over the 10-year timeframe, although additional surveillance data are needed. Strategies targeting the identified risk factors for developing P. kudriavzevii infections should be developed and tested for effectiveness and feasibility of implementation. Studies presenting data on epidemiology and susceptibility of P. kudriavzevii were scarce, especially in low- and middle-income countries (LMICs). Thus, global surveillance systems are required to monitor the incidence, susceptibility, and morbidity of P. kudriavzevii invasive infections to inform diagnosis and treatment. Timely species-level identification and susceptibility testing should be conducted to reduce the high mortality and limit the spread of P. kudriavzevii in healthcare facilities.<\/jats:p>","DOI":"10.1093\/mmy\/myad132","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T04:55:12Z","timestamp":1702270512000},"source":"Crossref","is-referenced-by-count":59,"title":["<i>Pichia kudriavzevii<\/i>\n                    (\n                    <i>Candida krusei<\/i>\n                    ): A systematic review to inform the World Health Organisation priority list of fungal pathogens"],"prefix":"10.1093","volume":"62","author":[{"given":"Thi Anh","family":"Nguyen","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Sydney, NSW , Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Yejin","family":"Kim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Sydney, NSW , Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"},{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie","family":"Stocker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Sydney, NSW , Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"},{"name":"Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-4178","authenticated-orcid":false,"given":"Sarah","family":"Kidd","sequence":"additional","affiliation":[{"name":"National Mycology Reference Centre, Microbiology and Infectious Diseases, SA Pathology , Adelaide, SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4405","authenticated-orcid":false,"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[{"name":"Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III , Majadahonda, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-2975","authenticated-orcid":false,"given":"Aiken","family":"Dao","sequence":"additional","affiliation":[{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"},{"name":"Westmead Institute for Medical Research , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harrison","sequence":"additional","affiliation":[{"name":"Institute of Infection and Immunity, St George's University London , London , UK"},{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5792","authenticated-orcid":false,"given":"Retno","family":"Wahyuningsih","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia , Jakarta , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Rickerts","sequence":"additional","affiliation":[{"name":"Robert Koch Institute , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Perfect","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Denning","sequence":"additional","affiliation":[{"name":"Manchester Fungal Infection Group (MFIG), Manchester Academic Health Science Centre, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-0014","authenticated-orcid":false,"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cassini","sequence":"additional","affiliation":[{"name":"Cantonal Doctor Office, Public Health Department, Canton of Vaud , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-1559","authenticated-orcid":false,"given":"Justin","family":"Beardsley","sequence":"additional","affiliation":[{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"},{"name":"Westmead Institute for Medical Research , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gigante","sequence":"additional","affiliation":[{"name":"AMR Division, World Health Organisation , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Sati","sequence":"additional","affiliation":[{"name":"AMR Division, World Health Organisation , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Orla","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Health , Melbourne, VIC , Australia"},{"name":"Department of Infectious Diseases, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Sydney, NSW , Australia"},{"name":"Sydney Infectious Diseases Institute, The University of Sydney , Sydney, NSW , Australia"},{"name":"Department of Pharmacy, Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"4","key":"2024062717020491300_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2024062717020491300_bib2","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2024062717020491300_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062717020491300_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/mmy\/myaa031","article-title":"Update on Candida krusei, a potential multidrug-resistant pathogen","volume":"59","author":"Jamiu","year":"2021","journal-title":"Med Mycol"},{"issue":"11","key":"2024062717020491300_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10096-002-0822-1","article-title":"Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death","volume":"21","author":"Viudes","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"17","key":"2024062717020491300_bib6","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1001\/archinte.160.17.2659","article-title":"Candida krusei fungemia. An escalating serious infection in immunocompromised patients","volume":"160","author":"Abbas","year":"2000","journal-title":"Arch Intern Med"},{"key":"2024062717020491300_bib7","first-page":"1673","article-title":"Current aspects in the biology, pathogeny, and treatment of Candida krusei, a neglected fungal pathogen","volume-title":"Infect Drug Resist","author":"Gomez-Gaviria","year":"2020"},{"issue":"Database issue","key":"2024062717020491300_bib8","doi-asserted-by":"crossref","first-page":"D136","DOI":"10.1093\/nar\/gkr1178","article-title":"The NCBI Taxonomy database","volume":"40","author":"Federhen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2024062717020491300_bib9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"2024062717020491300_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2024062717020491300_bib11","doi-asserted-by":"crossref","first-page":"e24198","DOI":"10.1371\/journal.pone.0024198","article-title":"Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy","volume":"6","author":"Bassetti","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"2024062717020491300_bib12","first-page":"257","article-title":"Prolonged outbreak of Candida krusei candidemia in paediatric ward of tertiary care hospital","volume":"185","author":"Kaur","year":"2020","journal-title":"Mycopathologia"},{"issue":"2","key":"2024062717020491300_bib13","doi-asserted-by":"crossref","first-page":"ofx253","DOI":"10.1093\/ofid\/ofx253","article-title":"Creation and assessment of a clinical predictive calculator and mortality associated with Candida krusei bloodstream infections","volume":"5","author":"Kronen","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"2024062717020491300_bib14","first-page":"821","article-title":"Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia","volume":"35","author":"Omrani","year":"2014","journal-title":"Saudi Med J"},{"issue":"7","key":"2024062717020491300_bib15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3201\/eid2407.171087","article-title":"Large outbreaks of fungal and bacterial bloodstream infections in a neonatal unit, South Africa, 2012\u20132016","volume":"24","author":"van\u00a0Schalkwyk","year":"2018","journal-title":"Emerg Infect. Dis."},{"issue":"5","key":"2024062717020491300_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/IPC.0000000000000403","article-title":"Candidemia in cancer patients: a retrospective analysis at a cancer center from 2001 to 2014","volume":"24","author":"Yacoub","year":"2016","journal-title":"Infectious Diseases in Clinical Practice"},{"key":"2024062717020491300_bib17","volume-title":"Epidemiological Cutoff Values for Antifungal Susceptibility Testing","year":"2016"},{"key":"2024062717020491300_bib18","article-title":"Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"issue":"1","key":"2024062717020491300_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1186\/s12879-017-2825-7","article-title":"Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates","volume":"17","author":"Badiee","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2024062717020491300_bib20","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.1111\/1469-0691.12212","article-title":"Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme","volume":"19","author":"Arendrup","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2024062717020491300_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fcimb.2019.00352","article-title":"The epidemiology and susceptibility of candidemia in Jerusalem, Israel","volume":"9","author":"Israel","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"2024062717020491300_bib22","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2024062717020491300_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/ijmm.IJMM_20_112","article-title":"Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility","volume":"38","author":"Kaur","year":"2020","journal-title":"Indian J Med Microbiol"},{"issue":"1-2","key":"2024062717020491300_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"issue":"4","key":"2024062717020491300_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","article-title":"Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"2024062717020491300_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-020-4883-5","article-title":"Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia","volume":"20","author":"Seyoum","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2024062717020491300_bib27","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1111\/1469-0691.12212","article-title":"Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme","volume":"19","author":"Arendrup","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062717020491300_bib28","doi-asserted-by":"crossref","first-page":"105799","DOI":"10.1016\/j.ijantimicag.2019.09.003","article-title":"Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination","volume":"55","author":"Castanheira","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2024062717020491300_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2014.06.007","article-title":"Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections","volume":"44","author":"Castanheira","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2024062717020491300_bib30","doi-asserted-by":"crossref","first-page":"e19494","DOI":"10.1097\/MD.0000000000019494","article-title":"A multicenter retrospective analysis of the antifungal susceptibility patterns of Candida species and the predictive factors of mortality in South Korean patients with candidemia","volume":"99","author":"Jung","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2024062717020491300_bib31","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3314\/mmj.17-00014","article-title":"National trends in the distribution of Candida species causing candidemia in Japan from 2003 to 2014","volume":"59","author":"Kakeya","year":"2018","journal-title":"Med Mycol J"},{"key":"2024062717020491300_bib32","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/IDR.S176384","article-title":"Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment","volume":"11","author":"Lausch","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"5","key":"2024062717020491300_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jinf.2017.12.018","article-title":"Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study","volume":"76","author":"Orasch","year":"2018","journal-title":"J Infect"},{"issue":"6","key":"2024062717020491300_bib34","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","article-title":"Impact of therapeutic strategies on the prognosis of candidemia in the ICU","volume":"42","author":"Puig-Asensio","year":"2014","journal-title":"Crit Care Med"},{"issue":"3","key":"2024062717020491300_bib35","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01516-19","article-title":"Epidemiological trends of fungemia in Greece with a focus on candidemia during the recent financial crisis: a 10-year survey in a tertiary care academic hospital and review of literature","volume":"64","author":"Siopi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"2024062717020491300_bib36","doi-asserted-by":"crossref","first-page":"iv48","DOI":"10.1093\/jac\/dkz287","article-title":"Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study","volume":"74","author":"Fuller","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2024062717020491300_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/myc.12661","article-title":"Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study","volume":"60","author":"Sasso","year":"2017","journal-title":"Mycoses"},{"issue":"11","key":"2024062717020491300_bib38","first-page":"B4698","article-title":"Candida and candidaemia","volume":"60","author":"Arendrup","year":"2013","journal-title":"Susceptibility and epidemiology Dan Med J"},{"issue":"2","key":"2024062717020491300_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/clinids\/14.2.472","article-title":"Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis","volume":"14","author":"McQuillen","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2024062717020491300_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40168-018-0538-9","article-title":"Enterobacteriaceae are essential for the modulation of colitis severity by fungi","volume":"6","author":"Sovran","year":"2018","journal-title":"Microbiome"},{"issue":"1","key":"2024062717020491300_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40168-020-00899-6","article-title":"Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria","volume":"8","author":"Seelbinder","year":"2020","journal-title":"Microbiome"},{"issue":"6","key":"2024062717020491300_bib42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02552-20","article-title":"Influence of Fluconazole Administration on Gut Microbiome, Intestinal Barrier, and Immune Response in Mice","volume":"65","author":"Heng","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"2024062717020491300_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"2024062717020491300_bib44","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1128\/AAC.00690-11","article-title":"Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France","volume":"55","author":"Blanchard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2024062717020491300_bib45","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.37.9.1847","article-title":"Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients","volume":"37","author":"Wingard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717020491300_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2334-7-97","article-title":"A cluster of Candida krusei infections in a haematological unit","volume":"7","author":"Hautala","year":"2007","journal-title":"BMC Infect Dis"},{"issue":"11","key":"2024062717020491300_bib47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.ajic.2014.07.033","article-title":"Candida krusei fungemia in 7 neonates: clonality tracked to an infusate","volume":"42","author":"Rongpharpi","year":"2014","journal-title":"Am J Infect Control"},{"issue":"2","key":"2024062717020491300_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1469-0691.2010.03223.x","article-title":"Candida krusei reservoir in a neutropaenia unit: molecular evidence of a foe?","volume":"17","author":"Ricardo","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062717020491300_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/ALN.0000000000002864","article-title":"Practice Guidelines for Central Venous Access 2020: An Updated Report by the American Society of Anesthesiologists Task Force on Central Venous Access","volume":"132","year":"2020","journal-title":"Anesthesiology"},{"issue":"7","key":"2024062717020491300_bib50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/653616","article-title":"Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center","volume":"31","author":"Apisarnthanarak","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"2024062717020491300_bib51","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1086\/319763","article-title":"Prophylactic antifungal therapy in the intensive care unit","volume":"32","author":"Rex","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2024062717020491300_bib52","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1128\/JCM.03239-14","article-title":"Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol","volume":"53","author":"Lau","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2024062717020491300_bib53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12154-014-0121-1","article-title":"Resistance to antifungals that target CYP51","volume":"7","author":"Parker","year":"2014","journal-title":"Journal of Chemical Biology"},{"issue":"2","key":"2024062717020491300_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(02)00181-0","article-title":"Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences","volume":"2","author":"Sanglard","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2024062717020491300_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/mmy.39.1.109.116","article-title":"Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei","volume":"39","author":"Katiyar","year":"2001","journal-title":"Med Mycol"},{"issue":"2","key":"2024062717020491300_bib56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/AAC.01095-08","article-title":"Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei","volume":"53","author":"Lamping","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2024062717020491300_bib57","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2024062717020491300_bib58","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2024062717020491300_bib59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12281-020-00388-1","article-title":"Review of the current management of urinary tract infections due to fluconazole-resistant and non-albicans Candida species","volume":"14","author":"Tan","year":"2020","journal-title":"Current Fungal Infection Reports"},{"key":"2024062717020491300_bib60","article-title":"Performance standards for antifungal susceptibility testing of yeasts","volume-title":"CLSI supplement M60","year":"2017"},{"issue":"12","key":"2024062717020491300_bib61","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717020491300_bib62","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","year":"2008"},{"issue":"3","key":"2024062717020491300_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/jof3030041","article-title":"Strategies to reduce mortality in adult and neonatal candidemia in developing countries","volume":"3","author":"Kaur","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2024062717020491300_bib64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Micro"},{"issue":"1","key":"2024062717020491300_bib65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12879-020-04985-w","article-title":"Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis","volume":"20","author":"Shi","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"5","key":"2024062717020491300_bib66","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jfma.2020.11.002","article-title":"High rates of misidentification of uncommon Candida species causing bloodstream infections using conventional phenotypic methods","volume":"120","author":"Huang","year":"2021","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"2024062717020491300_bib67","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/myc.13633","article-title":"Evaluation of the CHROMagar Candida Plus medium for presumptive identification of yeasts and MALDI-TOF MS identification","volume":"66","author":"Taverna","year":"2023","journal-title":"Mycoses"},{"issue":"2","key":"2024062717020491300_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1469-0691.12210","article-title":"Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species","volume":"20","author":"Lacroix","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062717020491300_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/dkac373","article-title":"Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin","volume":"78","author":"Arendrup","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2024062717020491300_bib70","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1093\/jac\/dkac288","article-title":"Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris","volume":"77","author":"Diaz-Garcia","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2024062717020491300_bib71","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2024062717020491300_bib72","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cmi.2015.06.010","article-title":"Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study","volume":"21","author":"Tan","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2024062717020491300_bib73","first-page":"63","article-title":"Epidemiology of fungal diseases in Africa: a review of diagnostic drivers","volume":"7","author":"Bongomin","year":"2021","journal-title":"Curr Med Mycol"},{"issue":"1","key":"2024062717020491300_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12992-019-0465-y","article-title":"A narrative review of health research capacity strengthening in low and middle-income countries: lessons for conflict-affected areas","volume":"15","author":"Bowsher","year":"2019","journal-title":"Global Health"},{"key":"2024062717020491300_bib75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jgar.2019.04.003","article-title":"First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey","volume":"18","author":"Arikan-Akdagli","year":"2019","journal-title":"Journal of Global Antimicrobial Resistance"},{"issue":"1","key":"2024062717020491300_bib76","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1186\/s12879-018-3512-z","article-title":"Correlation between antifungal consumption and the distribution of Candida species in different hospital departments of a Lebanese medical Centre","volume":"18","author":"Awad","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2024062717020491300_bib77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/myc.12553","article-title":"Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints","volume":"60","author":"Chen","year":"2017","journal-title":"Mycoses"},{"issue":"5","key":"2024062717020491300_bib78","doi-asserted-by":"crossref","first-page":"634.e1","DOI":"10.1016\/j.cmi.2019.02.007","article-title":"Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017)","volume":"25","author":"Desnos-Ollivier","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2024062717020491300_bib79","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12223-017-0525-8","article-title":"Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients","volume":"62","author":"Hrabovsky","year":"2017","journal-title":"Folia Microbiol (Praha)"},{"issue":"1","key":"2024062717020491300_bib80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","article-title":"Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)","volume":"38","author":"Pfaller","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"2024062717020491300_bib81","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.cmi.2019.04.027","article-title":"Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex","volume":"25","author":"Salse","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2024062717020491300_bib82","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/mmy\/myx094","article-title":"Mixed yeast infections in Taiwan","volume":"56","author":"Yang","year":"2018","journal-title":"Med Mycol"},{"issue":"1","key":"2024062717020491300_bib83","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s12879-019-4588-9","article-title":"Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China","volume":"19","author":"Zeng","year":"2019","journal-title":"BMC Infect Dis"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/6\/myad132\/58350541\/myad132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/6\/myad132\/58350541\/myad132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:17:55Z","timestamp":1719505075000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad132\/7700351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad132","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6]]},"article-number":"myad132"}}